Lindenmeyer, Maja T. http://orcid.org/0000-0003-4162-9107
Alakwaa, Fadhl
Rose, Michael
Kretzler, Matthias
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 23 December 2020
Accepted: 28 April 2021
First Online: 24 May 2021
Declarations
:
: Dr. Kretzler reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, Astra-Zeneca, NovoNordisk, Eli Lilly, Gilead, Goldfinch Bio, Merck, Chan Zuckerberg Initiative, Janssen, Boehringer-Ingelheim, Moderna, Chinook, amfAR, Angion, RenalytixAI, Retrophin, European Union Innovative Medicine Initiative, and Certa outside the submitted work. In addition, Dr. Kretzler has a patent PCT/EP2014/073413 “Biomarkers and methods for progression prediction for chronic kidney disease” licensed.